Retatrutide Peptide – Triple Agonist (GLP-1/GIP/Glucagon) | Ultra-Pure 99% for Advanced Fat Loss & Metabolic Research

Welcome to the next generation of peptide science. Retatrutide is a revolutionary triple agonist targeting GLP-1, GIP, and Glucagon receptors—delivering unmatched potential in fat loss, energy regulation, and metabolic health. Now available in ultra-pure 99% pharmaceutical-grade form for high-performance research and experimental protocols.

Backed by breakthrough clinical studies, Retatrutide is rapidly becoming a leading candidate in obesity and metabolic disorder research—demonstrating superior results to Semaglutide and Tirzepatide in early trials.

Why Choose Our Retatrutide (99% Purity)?

• Triple Receptor Agonist
  Simultaneously targets GLP-1, GIP, and Glucagon pathways for amplified fat-burning, insulin sensitivity, and appetite regulation.

• 99% Purity – Research Grade
  HPLC-tested to ensure minimal impurities, delivering stable and consistent outcomes in lab settings.

• Extended Half-Life
  Modified for prolonged duration of action—ideal for weekly dosing protocols in preclinical studies.

• Superior Fat Loss Potential
  Early data suggests greater weight reduction and improved glycemic control compared to GLP-1-only peptides.

Product Specs

• Purity: ≥99% (HPLC Verified)

• Form: Lyophilized powder (2mg or 5mg sterile vial)

• Storage: Store dry at –20°C. Reconstituted solution remains stable for 7–10 days refrigerated.

Research Applications

• Obesity and weight management models

• Type 2 diabetes and insulin signaling studies

• Appetite and energy balance research

• GLP-1/GIP/glucagon receptor pharmacology

Important Notice

This product is sold strictly for research purposes only. Not intended for human use, diagnostic procedures, or therapeutic applications. Use only in controlled laboratory environments in accordance with applicable laws and safety guidelines.